Also presented recently from the podium at the European Association of Neurological Societies in September was a retrospective review of more than 1,000 patients treated with PDD that found that 79 percent of patients reported "excellent" or "good" alleviation of pain and symptoms, with a procedure-related complication rate of less than 0.6 percent through 12 months. The study was conducted by Dr. Alberto Alexandre, MD, director of the European Neurosurgical Institute, Treviso, Italy. The study will also be presented from the podium at the World Federation of Neurological Societies Annual Meeting in November.
PDD is indicated for the treatment of patients with symptoms associated with a contained disc herniation. The procedure utilizes Coblation(R), a patented technology that uses electrical energy combined with a conductive medium, such as saline solution, to form a plasma that gently and precisely dissolves soft tissue, such as disc nucleus, at relatively low temperatures, minimizing damage to adjacent, healthy tissue. The result is that when a portion of the disc nucleus is removed, the herniated disc is decompressed. Approximately 100,000 PDD procedures have been performed to date. The Federal Food and Drug Administration cleared Coblation for use in PDD procedures in 2001.
Founded in 1993, ArthroCare Corporation (http://www.arthrocare.com) is
a highly innovative, multi-business medical device company that develops,
manufactures and markets minimally invasive surgical products. With these
products, ArthroCare targets a multi-billion dollar market opportunity
|SOURCE ArthroCare Corporation|
Copyright©2007 PR Newswire.
All rights reserved